About Antigenics

Antigenics’ mission is to enhance and extend lives through the development of superior health care products for a wide range of cancers, infectious diseases and autoimmune disorders.

Lead Products in Development at Antigenics

Oncophage® (vitespen; heat shock protein technology). In April 2008, Oncophage was approved in Russia for the treatment of kidney cancer patients at intermediate risk for disease recurrence. The company expects to launch Oncophage in Russia in the second half of 2008. Oncophage is approved only in Russia and Antigenics expects to submit to the European Regulatory Agency before the end of 2008.

Outside Russia, Oncophage is an investigational patient-specific vaccine designed to treat cancer with the intent of minimizing side effects. Currently being evaluated in clinical trials, treatment with Oncophage is designed to target only cancerous cells — not healthy normal cells. As a result, Oncophage is designed to limit the toxicities associated with traditional broad-acting cancer treatments.

Aroplatin™ and ATRA-IV. Investigational liposomal formulations of existing classes of drugs that have been designed to offer potentially increased efficacy and bioavailability. Aroplatin is being evaluated in a Phase 1 trial in solid tumors and B-cell lymphoma. The company is currently evaluating its ATRA-IV clinical development program.

AG-707. An investigational vaccine for genital herpes treatment based on proprietary heat shock protein technology. This off-the-shelf formulation is in Phase 1 testing.

QS-21. One of the world’s most widely studied immune adjuvants. This investigational adjuvant is being tested in several advanced clinical vaccine programs in partnership with leading pharmaceutical companies.

In the 13 years since its inception, Antigenics has achieved important milestones:

• Advanced six products in clinical trials, including Phase 3 trials
• Built on five technology platforms
• Established a strong intellectual property position in its core technologies, with more than 80 issued US patents

Antigenics has made two acquisitions that fit in well with its overall strategy: Aronex Pharmaceuticals, a company with products that treat cancer using novel drug formulations designed to reduce toxicity and increase efficacy, and Aquila Biopharmaceuticals, with products built on an immunology technology platform.

Antigenics has corporate offices in New York City, and research, development and manufacturing facilities in Lexington, Massachusetts.